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Simplified Analogs of Bryostatin
with Anticancer Activity Display Greater
Potency for Translocation of PKC-GFP
of PKC isozymes to different subcellular locations is
believed to be at least partly responsible for controlling
the substrate selectivity of PKC by localizing the enzyme
near its substrates but away from other proteins [11].
In an effort to create compounds with bryostatin-like
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Stanford University oped simplified analogs of bryostatin (Figure 1) [12–14].
When tested for binding to PKC, these analogs dis-Stanford, California 94305
played equal or greater potency than bryostatin 1. Fur-
ther testing against several human cancer cell lines dem-
onstrated that the analogs are up to two to three ordersSummary
of magnitude more potent than the natural product
against several cancer types [15]. Taken together, theseStructurally simplified analogs of bryostatin 1, a ma-
data suggest that the biological activity of these com-rine natural product in clinical trials for the treatment
pounds in complex systems might not be directly relatedof cancer, have been shown to be up to 50 times more
to their binding affinity to PKC mixtures. A lack of corre-potent than bryostatin 1 at inducing the translocation
lation between binding affinity and biological activity isof PKC-GFP from the cytosol of rat basophilic leuke-
well precedented in the diverging effects of the phorbolmia (RBL) cells. The end distribution of the protein is
esters and bryostatin. Both are potent activators of PKC,similar for all three compounds, despite a significant
but bryostatin is an antagonist for the tumor promotingdifference in translocation kinetics. The potency of the
effects of the phorbol esters [16]. A possible explanationcompounds for inducing the translocation response
for this divergence is that the activation of PKC by bryo-appears to be only qualitatively related to their binding
statin might result in differences in PKC localization oraffinity for PKC, highlighting the importance of using
isozyme specificity from that of the phorbol esters.binding affinity in conjunction with real-time measure-
Due to the coupling of PKC translocation to its activa-ments of protein localization for the pharmacological
tion, PKC-green fluorescent protein (GFP) fusion pro-profiling of biologically active agents.
teins provide an excellent tool for studying the behavior
of PKC isozymes in response to various stimuli [12,
Introduction 17–19]. We chose this system to further study the func-
tional and kinetic effects of our analogs on PKC activa-
The bryostatins are a structurally novel family of marine tion and translocation in a cellular system. The PKC-
natural products that exhibit a unique and potent combi- GFP translocation assay allows the direct observation
nation of biological activities [1]. In addition to its ex- of the protein response in living cells, quantification of
traordinary potency against murine P388 leukemia, the the kinetics of translocation, and determination of the
lead member of this family, bryostatin 1, has been found cellular destination of translocation. From these data, a
to stimulate immune system responses [2], regulate apo- measurement of the relative functional performance of
ptotic function [3], reverse multidrug resistance [4, 5], and these agents in a cellular environment can be deter-
act synergistically with other oncolytic agents [6]. While mined. This type of measurement is likely to be more
the mode of action of bryostatin 1 is not established, it relevant to physiological effects than a measure of bind-
binds to protein kinase C (PKC) with high affinity and ing affinity since it measures directly the action of the
modulates its function [1, 7]. Other proteins containing ligand on its target in vitro as a function of time rather
C1 domains, such as RasGRP, Unc/Munc, and the chi- than a simple noncellular affinity as is the case for bind-
maerins, have also been implicated as possible receptor ing measurements. In addition to providing a quantifi-
targets for bryostatin [8, 9]. Despite its impressive bio- able output, this system allows the localization of the
logical profile, the advancement of bryostatin 1 as a protein to be observed. If localization is important for
therapeutic agent has been limited by its low natural activity and specificity of the enzyme, as is believed for
abundance and chemical complexity, which render it PKC, this could be a significant factor in the response.
and its derivatives chemically inaccessible.
Bryostatin, along with the phorbol esters and the en-
dogenous ligand diacyl glycerol (DAG), modulate PKC Results
activity by binding to the C1 domains of the protein
and inducing translocation from the cytosol to cellular The abilities of analogs 1 and 2 and bryostatin 1 to
membranes. While PKC can be activated without trans- induce translocation of PKC-GFP in RBL cells were
location, under most conditions translocation is an inte- compared at various concentrations. When expressed
gral part of the activation process and can be used as in this cell line, PKC-GFP is present throughout the cyto-
a surrogate measure for activation [10]. Translocation sol but not in the nucleus prior to treatment (Figure 2).
Exposure of RBL cells overexpressing PKC-GFP to
bryostatin 1 or the analogs resulted in a rapid transloca-*Correspondence: wenderp@stanford.edu
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Figure 1. Bryostatin 1 and the Structures of
Analogs 1 and 2
Shown are the binding affinities to a PKC mix-
ture isolated from rat brain.
tion of fluorescence from the cytosol to the plasma than 5 min for all three agents, as can be seen in Figure
2. Despite their difference in binding potency, analog 1membrane and the perinuclear region. Shown in Figures
2 and 3 is the response of the cells to each of the and 2 displayed essentially identical rates and degrees
of translocation at this concentration. An additional setthree agents at a concentration of 200 nM. For all three
compounds at 200 nM, the ratio of the average fluores- of experiments was performed at 37C to determine
the extent to which temperature influenced the relativecence intensity measured at the plasma membrane to
that at the nuclear membrane once translocation was rates. The results at 37C were indistinguishable from
those at room temperature (data not shown). Figure 4complete was approximately 1:1. All three ratios were
identical within error. shows the decrease in cytosolic fluorescence after the
addition of bryostatin 1, analog 1, or analog 2 (200 nM).In order to ensure that the observed nuclear mem-
brane localization was not a result of translocation of The data was measured as the decrease in cytosolic
fluorescence to avoid artifacts and difficulties relatedthe kinase domain-GFP fragment after proteolysis, RBL
cells were transfected with PKC-GFP and exposed to to ruffling and movement of the membrane, which was
observed in several of the experiments.bryostatin 1 (200 nM) or analog 2 (200 nM) for 30 min.
The lysates of these cells were examined by Western For all three compounds, both the rate of translocation
and the overall degree of translocation was dose de-blot with both a monoclonal anti-GFP antibody and a
polyclonal antibody to PKC. There was no increase pendent, with lower doses resulting in slower and less
complete translocation (Figures 5 and 6). At a givenin the amount of cleavage product in either the cells
exposed to bryostatin 1 or analog 2 when compared to concentration, analog 1 and 2 induced much faster
translocation than bryostatin 1. Shown in Figure 6 arecells that had not been exposed to any agent (data not
shown). This result is consistent with that obtained by plots of the measured half-lives for the translocation of
PKC-GFP in response to the analogs and bryostatin 1Blumberg and coworkers in PKC-GFP-overexpressing
CHO cells and indicates that the observed localization as well as the degree of translocation in response to
each agent. The measured half-life was calculated asto the nuclear membrane is induced by the test mole-
cules [18, 19]. the amount of time for the translocation to proceed
halfway to its observed end point. The degree of translo-At a concentration of 200 nM, translocation to the
plasma and nuclear membranes was complete in less cation is the ratio of the amount of fluorescence in the
Figure 2. Confocal Images Showing the Response of PKC-GFP in Transfected RBL Cells to Treatment with 200 nM Bryostatin 1, Analog 1,
or Analog 2 during a 30 min Time Course
Translocation of PKC-GFP by Analogs of Bryostatin
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Figure 3. Confocal Images Displaying the Localization of PKC-GFP at Both the Plasma Membrane and the Nuclear Membrane of RBL Cells
after Treatment with 200 nM Bryostatin 1, Analog 1, or Analog 2 for 30 min
cytosol at the end point of the experiment to the amount tion at 1 nM, analog 2 induced translocation even at a
concentration of 0.5 nM and was active, albeit margin-present before the addition of any agent. At concentra-
tions of 5 nM or greater, both analogs were found to have ally, even at a concentration of 0.1 nM. As can be seen
in Figure 5, a 100 pM concentration of analog 2 was asthe same rate of translocation. Both analogs induced a
translocation response that was approximately twice as effective at inducing translocation of PKC-GFP as 1 nM
of analog 1, which was as effective as 5 nM of bryo-fast as that induced by bryostatin 1. At 1 nM, however,
the rates diverged and analog 2 had a substantially statin 1.
faster rate of translocation compared to both analog 1
and bryostatin 1. Discussion
A similar effect was seen when the degree of translo-
cation was compared. At concentrations of 50 and 200 An understanding of why equipotent activators of PKC,
such as bryostatin and the phorbol esters, differ in theirnM, all three agents induced a similar degree of translo-
cation. At concentrations of 5 nM, the degree of translo- pharmacological responses is an important focus of
PKC research. While binding affinities to PKC can servecation induced by analog 1 and analog 2 remained simi-
lar, but was significantly greater than that induced by as indicators of potential interactions in biological sys-
tems, they often do not correlate with specific biologicalbryostatin 1. When dosed at 1 nM, the response of
PKC-GFP to analog 1 and analog 2 differed, with analog function. This is not surprising, as binding, a thermody-
namic parameter, is not always connected to function,2 resulting in greater translocation than analog 1 or bry-
ostatin 1. a kinetic parameter. For example, bryostatin and analog
1 have comparable binding affinities to PKC, whereasIn addition to the observed differences in kinetics, the
analogs also retained the ability to induce translocation both analogs 1 and 2 are orders of magnitude more
potent at inhibiting the growth of many human cancerof PKC-GFP at lower doses than bryostatin 1. Figure
7 shows images of the cells after exposure to the agents. cell lines [15]. In order to elucidate the cascade of events
that culminate in a cellular response to the phorbol es-Bryostatin 1 induced very little translocation at 5 nM,
while both analogs 1 and 2 were still effective at inducing ters, bryostatin, and analogs of bryostatin, a more com-
prehensive understanding of the response of PKC andtranslocation of PKC to the plasma membrane. While
treatment with analog 1 resulted in marginal transloca- other proteins that contain C1 binding domains is re-
Figure 4. Decrease in Cytosolic Fluores-
cence of RBL Cells Transfected with PKC-
GFP and Treated with 200 nM Bryostatin 1,
Analog 1, or Analog 2
The degree of fluorescence was normalized
to that present at the beginning of the experi-
ment, and the agents were added after the
fifth measurement at time  35 s.
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Figure 5. The Decrease in Cytosolic Fluorescence of PKC-GFP-Transfected RBL Cells after Treatment with Either Bryostatin 1, Analog 1, or
Analog 2 at Varying Concentrations
In all experiments, the agent was added after the 5th image at time  150 s. The degree of fluorescence is expressed relative to that present
at the start of the experiment.
quired. The use of fluorescently tagged proteins and localization of PKC-GFP constructs in response to the
tumor promoting phorbol esters differs from that seenconfocal microscopy enable one to observe the earliest
stages of such a functional response in real time. in response to bryostatin 1 or nontumor promoting ana-
logs of PMA [19]. Current understanding of PKC activityPKC is implicated as an important isozyme of PKC
for determining the response of living systems to tumor- attributes the substrate specificity of PKC at least in
part to its subcellular localization upon activation [22].ogenesis induced by the phorbol esters [20]. PKC is
integral to certain apoptosis pathways and might also Therefore, different patterns of localization of PKC iso-
zymes might account for the differing cellular responsesplay a role in the metastatic potential of cancer cells
[21]. Blumberg and coworkers have also shown that the to PKC activation. For these reasons, PKC-GFP fusion
Figure 6. Comparison of the Measured Half-Life and Degree of Translocation of PKC-GFP in Response to Varying Doses of Bryostatin 1,
Analog 1, or Analog 2 in RBL Cells
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Figure 7. Images of PKC-GFP-Transfected RBL Cells Treated with Varying Concentrations of Bryostatin 1, Analog 1, or Analog 2 Acquired
at the End of the Experiment, t  30–50 min
proteins were chosen for characterizing the relative the same for analog 1 and 2, but that these analogs are
both faster than bryostatin 1. However, between thefunction of bryostatin and its analogs.
The results of these experiments show that analogs ranges of 5 nM and 1 nM, the rate at which analogs 1 and
2 induce translocation PKC-GFP becomes different.1 and 2 are significantly more potent than bryostatin at
inducing translocation of PKC-GFP but induce a similar A possible explanation for the difference in transloca-
tion potency between bryostatin 1 and the analogs ispattern of translocation. At concentrations of 200 and
50 nM, bryostatin 1 induces an initial translocation of that the lipophilicity of these molecules might play a
role in determining the potency and rate of the cellularPKC-GFP to the plasma membrane. Translocation of
PKC-GFP to the nuclear membrane in response to bry- response. The modified spacer domains present in both
1 and 2 might alter their lipophilicity, which in turn couldostatin 1 is slower and is not observed until approxi-
mately 5–10 min after administration (Figure 2). In re- affect their diffusion through cells and partitioning among
various cellular compartments. As the binding event withsponse to 200 or 50 nM concentrations of analogs 1
and 2, however, there is a rapid localization of PKC- PKC and bryostatin 1 or the analogs involves a tertiary
complex of membrane, ligand, and protein, changingGFP to the plasma and nuclear membranes simultane-
ously. the interaction of the ligand with the membrane could
significantly alter the kinetics and thermodynamics ofAnother interesting result is that the rate of PKC-
GFP translocation at higher concentrations (5 nM) is the interaction.
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GIBCO) containing 20% fetal calf serum with 50 units/ml penicillin,Previous work in our group has suggested that the
50 g/ml streptomycin, and 4 mM glutamine (GIBCO). Cells werestructure of bryostatin 1 could be thought of in terms
maintained at 37C in an atmosphere of 10% CO2. Two hours priorof a recognition domain and a spacer domain [12–14].
to transfection, cells were plated onto sterile glass coverslips. The
The recognition domain, so-called because it contains mRNA encoding GFP-tagged full-length PKC was electroporated
all of the requisite functionality for recognition by, and into the cells 12 hr before experiments according to the procedure
binding to, PKC, consists of the C-ring moiety along described previously [23].
with the macrolactone carbonyl. It was thought that the
Fluorescence Microscopyspacer domain, which comprises the A and B rings of
Fluorescence images were obtained using the 488 nm excitationthe molecule, served to reduce the conformational free-
line of a laser scanning confocal microscope (Pascal, Zeiss), anddom of the recognition domain and keep the recognition
emission was collected through a 505–550 nm band-pass filter. Cells
elements in the proper orientation for binding to PKC. were imaged on the stage of an inverted microscope (Axiovert 100M)
It appears from the data presented here that changes using a 40 1.2 NA Zeiss Plan-apo oil immersion objective. For
to this region of the molecule also influence the translo- each experiment, a coverslip to which the cells adhered was used
cation response of PKC. to form the base of a metal cell chamber (Molecular Probes). Cells
were washed and maintained in Dulbecco’s phosphate bufferedThe translocation of PKC isoforms is only the initial
saline (GIBCO) supplemented with 10 mM glucose. Bryostatin, ana-response of these proteins to activators, and measuring
log 1, and analog 2 were dissolved in DMSO and then diluted tothe translocation rate in response to different agents
the desired concentration in the extracellular buffer shortly before
provides information on only the initial stage of their being added to the cells. The final concentration of DMSO to which
function. In many cases, treatment with PKC activators the cells were exposed did not exceed 0.1%. Unless otherwise
is followed by protein degradation, and the depletion of stated, each time series lasted 30 min, and images were acquired
every 30 s. Reagents were added to the cell chamber after the fifththe kinase from the cells might also account for some
image in each time series. For experiments performed at 37C, anof the observed action of these molecules. There is also
air stream incubator (ASI400, Nevtek) was used to heat the stagegrowing evidence that for activators of PKC that bind
and microscope objectives, and the extracellular buffer was warmedto the C1 domains of the protein, including bryostatin
to 37C before use.
and the phorbol esters, other proteins containing homol-
ogous C1 domains, such as the chimaerins, RasGRP, Analysis
and Munc, might play a role in regulating the cellular Images were exported as 12 bit files and analyzed using Metamorph
response. However, these studies help to underscore data analysis software (Universal Imaging). To monitor the transloca-
tion of PKC-delta, a small region of interest was selected in thethe large disconnect between potency in simple binding
cytosol of each cell, and fluorescence intensity values were graphedmodels and activity in more complex cellular systems.
against time following background subtraction and normalization.Such methods as used here might help in the more
detailed understanding of structure and function which
Bryostatin and Bryostatin Analogs
can then be used in the design of better, more specific, The bryostatin analogs used have been reported previously. The
and more potent agents with desired therapeutic func- C26 methyl analog [12–14] reported in 1998 is referred to as analog
tions. 1, and the C26 des-methyl analog [15] reported in 2002 is referred
to as analog 2.We have shown that, in contrast to their binding affini-
ties, synthetic analogs of bryostatin are more potent at
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